Results

1–8 of 8 results for intravitreal bevacizumab

Computerized Analysis of Retinal Vascular Growth Following Intravitreal Bevacizumab Monotherapy in Retinopathy of Prematurity Until Three Years of Age
Swati Agarwal-Sinha, MD, FASRS
Annual Meeting Talks
2021
Safety Results of ONS-5010, an Ophthalmic Bevacizumab, in Treated Eyes of Patients With Wet AMD, DME, and BRVO
Suber S. Huang, MD, MBA, FASRS
Annual Meeting Talks
2021
Low Incidence of Endopthalmitis After Intravitreal Injections in an Office Setting Without Gloves and Drapes With a Modified Technique
Kamal Kishore, MD, MBBS
On Demand Cases, Courses, and Papers
2020
Angiographic Review of Choroidal Involution in Eyes With Retinopathy of Prematurity Post Bevacizumab Treatment
Swati Agarwal-Sinha, MD, FASRS
Annual Meeting Talks
2020
Intravitreal Bevacizumab vs. Bevacizumab with Dexamethasone for the Treatment of Exudative Age-Related Macular Degeneration
Reda Issa, MD
On Demand Cases, Courses, and Papers
2019
Journal Club with Dr. Ferhina Ali and Dr. Daniel Chao Discussing Caffeine and Beta Blockers for Vitreoretinal Surgeons, Cost-Savings with Intravitreal Bevacizumab, and more
Jayanth Sridhar, MD
Daniel L Chao, MD, PhD
Ferhina S Ali, MD, MPH
Member Podcasts
2020
Preoperative Intravitreal Bevacizumab for TRD Secondary to PDR: A Prospective Randomized Clinical Trial of the PACORES Group
J. Fernando Arevalo, MD, PhD, FACS, FASRS
Annual Meeting Talks
2018
Fluorescein Angiography Findings Post-intravitreal Bevacizumab for ROP: Can It Predict the Late-Onset Risk of Recurrence?
Swati Agarwal-Sinha, MD, FASRS
Annual Meeting Talks
2018